sales@fnfresearch.com

USA: +1 347 690-0211 | UK: +44 2032 894158 | JAPAN: +81 50 5806 9039 | Translate : 

Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports
  1. Home
  2. Healthcare
  3. Gene Therapy Market
report img

Gene Therapy Market By Vector (Viral & Non-Viral), By Delivery Mode (In Vivo & Ex Vivo), By Indication (Neurological Diseases, Cancer, Duchenne Muscular Dystrophy, Hepatological Diseases, & Others), And By Regions - Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast 2021 - 2026

Covid-19

Gene Therapy Market

The pandemic continues to cause unprecedented disruption across industries worldwide.Get detailed insights regarding the impact of COVID-19 on the market. Request Sample

Industry Insights

[205+ Pages Report] We at Facts & Factors have recently published a report titled “Global Gene Therapy Market” that encompasses the spectacle of the market in an analytical and comprehensive manner. We at Facts & Factors estimate that the gene therapy market will be valued at USD 12.9 Billion in the year 2026 from an initial value of USD 2.7 Billion in the year 2020 at a CAGR value of 22.3%.

logoMarket Overview

Gene therapy is a medical binomial that allows for the modification of a person’s genes in order to develop antibodies for treating or curating diseases. Gene therapies can work by employing several mechanisms such as replacing a disease-causing gene with a healthy variation of the gene or by inactivating a disease-causing gene that does not have the proper functionality. Additionally, a mechanism can include introducing a newly modified gene into the body for further eliminating a disease. The variety of gene therapies that are currently available are plasmid DNA, viral vectors, bacterial vectors, human gene-editing technology, and patient-derived cellular gene therapy products, to name a few.

logoIndustry Growth Factors

The primary driving factors for the significant growth of the global gene therapy market are the increasing prevalence of cancer and other targeted disorders coupled with the rising availability of measures. Additionally, gene therapy is being granted several reimbursements from various insurance carriers which increases the revenue stream that can be generated for the market during the forecast period. Rising funding for gene therapy research coupled with the rising adoption of gene therapy therapeutics is expected to increase the footprint of the global gene therapy market during the forecast period. A dynamic competitive nature is expected to drive the market due to several initiatives that are undertaken by the key market players such as the biopharma companies.

The insurgence of the current pandemic is expected to create a positive impact on the global gene therapy market during the forecast period. The market is expected to increase in boundaries due to the added intervention of life-threatening diseases such as heart diseases, AIDS, cystic fibrosis, and age-related disorders. Rising investment in research and development activities is further expected to curate a larger market revenue for the global gene therapy market during the forecast period. However, high prices and irregular availability is expected to dim the market growth to a slower rate during the forecast period.

logoSegmentation Analysis

The global gene therapy market can be segmented into vectors, delivery methods, indications, and regions.

The global gene therapy market can be divided into viral and non-viral vectors on the basis of vectors. The segment pertaining to non-viral vectors is expected to witness the largest market share during the advent of the forecast owing to technological advancements for physicochemical approaches in materials such as lipid, naked DNA, chromosomes, plasmid, cationic polymers, and conjugate complexes to name a few. The global gene therapy market can be fragmented into in vivo and ex vivo on the basis of delivery mode. The ex vivo segment is expected to occupy the largest market share during the advent of the forecast owing to a safer mode of operation and easy deliverables to name a few. The global gene therapy market can be broken down into neurological diseases, cancer, Duchenne muscular dystrophy, hepatological diseases, and others on the basis of indication. The segment pertaining to cancer is expected to witness the largest market share during the advent forecast period owing to the rising approval of gene therapies for the treatment of cancer coupled with the increasing prevalence of hematologic cancers to name a few.

Report Attribute

Details

Market Size in 2020

USD 2.7 Billion

Projected Market Size in 2026

USD 12.9 Billion

CAGR Growth Rate

22.3%

Base Year

2020

Forecast Years

2021-2006

Key Market Players

Bluebird Bio, Inc., TaxusCardium Pharmaceutical Group, Inc., UniQure N.V., Shire Plc, Cellectis S.A. and Others

Key Segments

Vectors, Delivery Mode, Indications, and Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

logo Regional Analysis

North America is expected to witness the largest market share during the forecast period in terms of global revenue contribution. The factors that contribute to the market dominance on a global scale can be attributed to the rising prevalence of chronic diseases coupled with a high and growing healthcare expenditure to name a few. Additionally, integration of advanced healthcare infrastructure coupled with readily available reimbursements measures are expected to increase the footprint of the gene therapy market in the region. Increasing key market players in the region coupled with favorable regulatory approval are expected to project the gene therapy market on a steadfast path during the forecast period.

logo Competitive Players

The key market participants for the global gene therapy market are REGENBIO, Inc., Oxford BioMedicaPlc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, Applied Genetics Technologies Corporation, Bluebird Bio, Inc., TaxusCardium Pharmaceutical Group, Inc., UniQure N.V., Shire Plc, Cellectis S.A., Sangamo Therapeutics, Inc., Gilead Lifesciences, Inc., and Shanghai Sunway Biotech Co. Ltd., among others.

logo By Vectors Segment Analysis

  • Viral
    • Retroviral Vector
      • Gammaretroviral Vector
      • Lentiviral Vector
    • Adeno-Associated Vector
    • Other Viral Vectors
  • Non-Viral
    • Oligonucleotides

logo By Delivery ModeSegment Analysis

  • In Vivo
  • Ex Vivo

logo By IndicationSegment Analysis

  • Neurological Diseases
  • Cancer
  • Duchenne Muscular Dystrophy
  • Hepatological Diseases
  • Others

logo By Regional Segment Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of MEA

Covid-19

Gene Therapy Market

The pandemic continues to cause unprecedented disruption across industries worldwide.Get detailed insights regarding the impact of COVID-19 on the market. Request Sample

Table of Content

  1. Chapter 1 Executive Summary
    1. 1.1. Introduction of Gene Therapy
    2. 1.2. Global Gene Therapy Market, 2019 & 2026 (USD Billion)
    3. 1.3. Global Gene Therapy Market, 2016 – 2026 (USD Billion)
    4. 1.4. Global Gene Therapy Market Absolute Revenue Opportunity, 2016 – 2026 (USD Billion)
    5. 1.5. Global Gene Therapy Market Incremental Revenue Opportunity, 2020 – 2026 (USD Billion)
  2. Chapter 2 Gene Therapy Market – Vectors Analysis
    1. 2.1. Global Gene Therapy Market – Vectors Overview
    2. 2.2. Global Gene Therapy Market Share, by Vectors , 2019 & 2026 (USD Billion)
    3. 2.3. Viral
      1. 2.3.1. Global Viral Gene Therapy Market, 2016 – 2026 (USD Billion)
    4. 2.4. Non-Viral
      1. 2.4.1. Global Non-Viral Gene Therapy Market, 2016 – 2026 (USD Billion)
  3. Chapter 3 Gene Therapy Market – Delivery Mode Analysis
    1. 3.1. Global Gene Therapy Market – Delivery Mode Overview
    2. 3.2. Global Gene Therapy Market Share, by Delivery Mode , 2019 & 2026 (USD Billion)
    3. 3.3. In Vivo
      1. 3.3.1. Global In Vivo Gene Therapy Market, 2016 – 2026 (USD Billion)
    4. 3.4. Ex Vivo
      1. 3.4.1. Global Ex Vivo Gene Therapy Market, 2016 – 2026 (USD Billion)
  4. Chapter 4 Gene Therapy Market – Indication Analysis
    1. 4.1. Global Gene Therapy Market – Indication Overview
    2. 4.2. Global Gene Therapy Market Share, by Indication, 2019 & 2026 (USD Billion)
    3. 4.3. Neurological Diseases
      1. 4.3.1. Global Neurological Diseases Gene Therapy Market, 2016 – 2026 (USD Billion)
    4. 4.4. Cancer
      1. 4.4.1. Global Cancer Gene Therapy Market, 2016 – 2026 (USD Billion)
    5. 4.5. Duchenne Muscular Dystrophy
      1. 4.5.1. Global Duchenne Muscular Dystrophy Gene Therapy Market, 2016 – 2026 (USD Billion)
    6. 4.6. Hepatological Diseases
      1. 4.6.1. Global Hepatological Diseases Gene Therapy Market, 2016 – 2026 (USD Billion)
    7. 4.7. Others
      1. 4.7.1. Global Others Gene Therapy Market, 2016 – 2026 (USD Billion)
  5. Chapter 5 Gene Therapy Market – Regional Analysis
    1. 5.1. Global Gene Therapy Market Regional Overview
    2. 5.2. Global Gene Therapy Market Share, by Region, 2019 & 2026 (USD Billion)
    3. 5.3. North America
      1. 5.3.1. North America Gene Therapy Market, 2016 – 2026 (USD Billion)
        1. 5.3.1.1. North America Gene Therapy Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.3.2. North America Gene Therapy Market, by Vectors , 2016 – 2026
        1. 5.3.2.1. North America Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
      3. 5.3.3. North America Gene Therapy Market, by Delivery Mode , 2016 – 2026
        1. 5.3.3.1. North America Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
      4. 5.3.4. North America Gene Therapy Market, by Indication, 2016 – 2026
        1. 5.3.4.1. North America Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
      5. 5.3.5. U.S.
        1. 5.3.5.1. U.S. Gene Therapy Market, 2016 – 2026 (USD Billion)
      6. 5.3.6. Canada
        1. 5.3.6.1. Canada Gene Therapy Market, 2016 – 2026 (USD Billion)
    4. 5.4. Europe
      1. 5.4.1. Europe Gene Therapy Market, 2016 – 2026 (USD Billion)
        1. 5.4.1.1. Europe Gene Therapy Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.4.2. Europe Gene Therapy Market, by Vectors , 2016 – 2026
        1. 5.4.2.1. Europe Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
      3. 5.4.3. Europe Gene Therapy Market, by Delivery Mode , 2016 – 2026
        1. 5.4.3.1. Europe Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
      4. 5.4.4. Europe Gene Therapy Market, by Indication, 2016 – 2026
        1. 5.4.4.1. Europe Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
      5. 5.4.5. Germany
        1. 5.4.5.1. Germany Gene Therapy Market, 2016 – 2026 (USD Billion)
      6. 5.4.6. France
        1. 5.4.6.1. France Gene Therapy Market, 2016 – 2026 (USD Billion)
      7. 5.4.7. U.K.
        1. 5.4.7.1. U.K. Gene Therapy Market, 2016 – 2026 (USD Billion)
      8. 5.4.8. Italy
        1. 5.4.8.1. Italy Gene Therapy Market, 2016 – 2026 (USD Billion)
      9. 5.4.9. Spain
        1. 5.4.9.1. Spain Gene Therapy Market, 2016 – 2026 (USD Billion)
      10. 5.4.10. Rest of Europe
        1. 5.4.10.1. Rest of Europe Gene Therapy Market, 2016 – 2026 (USD Billion)
    5. 5.5. Asia Pacific
      1. 5.5.1. Asia Pacific Gene Therapy Market, 2016 – 2026 (USD Billion)
        1. 5.5.1.1. Asia Pacific Gene Therapy Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.5.2. Asia Pacific Gene Therapy Market, by Vectors , 2016 – 2026
        1. 5.5.2.1. Asia Pacific Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
      3. 5.5.3. Asia Pacific Gene Therapy Market, by Delivery Mode , 2016 – 2026
        1. 5.5.3.1. Asia Pacific Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
      4. 5.5.4. Asia Pacific Gene Therapy Market, by Indication, 2016 – 2026
        1. 5.5.4.1. Asia Pacific Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
      5. 5.5.5. China
        1. 5.5.5.1. China Gene Therapy Market, 2016 – 2026 (USD Billion)
      6. 5.5.6. Japan
        1. 5.5.6.1. Japan Gene Therapy Market, 2016 – 2026 (USD Billion)
      7. 5.5.7. India
        1. 5.5.7.1. India Gene Therapy Market, 2016 – 2026 (USD Billion)
      8. 5.5.8. South Korea
        1. 5.5.8.1. South Korea Gene Therapy Market, 2016 – 2026 (USD Billion)
      9. 5.5.9. South-East Asia
        1. 5.5.9.1. South-East Asia Gene Therapy Market, 2016 – 2026 (USD Billion)
      10. 5.5.10. Rest of Asia Pacific
        1. 5.5.10.1. Rest of Asia Pacific Gene Therapy Market, 2016 – 2026 (USD Billion)
    6. 5.6. Latin America
      1. 5.6.1. Latin America Gene Therapy Market, 2016 – 2026 (USD Billion)
        1. 5.6.1.1. Latin America Gene Therapy Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.6.2. Latin America Gene Therapy Market, by Vectors , 2016 – 2026
        1. 5.6.2.1. Latin America Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
      3. 5.6.3. Latin America Gene Therapy Market, by Delivery Mode , 2016 – 2026
        1. 5.6.3.1. Latin America Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
      4. 5.6.4. Latin America Gene Therapy Market, by Indication, 2016 – 2026
        1. 5.6.4.1. Latin America Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
      5. 5.6.5. Brazil
        1. 5.6.5.1. Brazil Gene Therapy Market, 2016 – 2026 (USD Billion)
      6. 5.6.6. Mexico
        1. 5.6.6.1. Mexico Gene Therapy Market, 2016 – 2026 (USD Billion)
      7. 5.6.7. Rest of Latin America
        1. 5.6.7.1. Rest of Latin America Gene Therapy Market, 2016 – 2026 (USD Billion)
    7. 5.7. The Middle-East and Africa
      1. 5.7.1. The Middle-East and Africa Gene Therapy Market, 2016 – 2026 (USD Billion)
        1. 5.7.1.1. The Middle-East and Africa Gene Therapy Market, by Country, 2016 - 2026 (USD Billion)
      2. 5.7.2. The Middle-East and Africa Gene Therapy Market, by Vectors , 2016 – 2026
        1. 5.7.2.1. The Middle-East and Africa Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
      3. 5.7.3. The Middle-East and Africa Gene Therapy Market, by Delivery Mode , 2016 – 2026
        1. 5.7.3.1. The Middle-East and Africa Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
      4. 5.7.4. The Middle-East and Africa Gene Therapy Market, by Indication, 2016 – 2026
        1. 5.7.4.1. The Middle-East and Africa Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
      5. 5.7.5. GCC Countries
        1. 5.7.5.1. GCC Countries Gene Therapy Market, 2016 – 2026 (USD Billion)
      6. 5.7.6. South Africa
        1. 5.7.6.1. South Africa Gene Therapy Market, 2016 – 2026 (USD Billion)
      7. 5.7.7. Rest of Middle-East Africa
        1. 5.7.7.1. Rest of Middle-East Africa Gene Therapy Market, 2016 – 2026 (USD Billion)
  6. Chapter 6 Gene Therapy Market – Competitive Landscape
    1. 6.1. Competitor Market Share – Revenue
    2. 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    3. 6.3. Strategic Developments
      1. 6.3.1. Acquisitions and Mergers
      2. 6.3.2. New Products
      3. 6.3.3. Research & Development Activities
  7. Chapter 7 Company Profiles
    1. 7.1. REGENBIO Inc
      1. 7.1.1. Company Overview
      2. 7.1.2. Product/Service Portfolio
      3. 7.1.3. REGENBIO Inc Sales, Revenue, and Gross Margin
      4. 7.1.4. REGENBIO Inc Revenue and Growth Rate
      5. 7.1.5. REGENBIO Inc Market Share
      6. 7.1.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    2. 7.2. Oxford BioMedica Plc
      1. 7.2.1. Company Overview
      2. 7.2.2. Product/Service Portfolio
      3. 7.2.3. Oxford BioMedica Plc Sales, Revenue, and Gross Margin
      4. 7.2.4. Oxford BioMedica Plc Revenue and Growth Rate
      5. 7.2.5. Oxford BioMedica Plc Market Share
      6. 7.2.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    3. 7.3. Dimension Therapeutics Inc
      1. 7.3.1. Company Overview
      2. 7.3.2. Product/Service Portfolio
      3. 7.3.3. Dimension Therapeutics Inc Sales, Revenue, and Gross Margin
      4. 7.3.4. Dimension Therapeutics Inc Revenue and Growth Rate
      5. 7.3.5. Dimension Therapeutics Inc Market Share
      6. 7.3.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    4. 7.4. Bristol-Myers Squibb Company
      1. 7.4.1. Company Overview
      2. 7.4.2. Product/Service Portfolio
      3. 7.4.3. Bristol-Myers Squibb Company Sales, Revenue, and Gross Margin
      4. 7.4.4. Bristol-Myers Squibb Company Revenue and Growth Rate
      5. 7.4.5. Bristol-Myers Squibb Company Market Share
      6. 7.4.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    5. 7.5. SANOFI
      1. 7.5.1. Company Overview
      2. 7.5.2. Product/Service Portfolio
      3. 7.5.3. SANOFI Sales, Revenue, and Gross Margin
      4. 7.5.4. SANOFI Revenue and Growth Rate
      5. 7.5.5. SANOFI Market Share
      6. 7.5.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    6. 7.6. Applied Genetics Technologies Corporation
      1. 7.6.1. Company Overview
      2. 7.6.2. Product/Service Portfolio
      3. 7.6.3. Applied Genetics Technologies Corporation Sales, Revenue, and Gross Margin
      4. 7.6.4. Applied Genetics Technologies Corporation Revenue and Growth Rate
      5. 7.6.5. Applied Genetics Technologies Corporation Market Share
      6. 7.6.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    7. 7.7. Bluebird Bio Inc
      1. 7.7.1. Company Overview
      2. 7.7.2. Product/Service Portfolio
      3. 7.7.3. Bluebird Bio Inc Sales, Revenue, and Gross Margin
      4. 7.7.4. Bluebird Bio Inc Revenue and Growth Rate
      5. 7.7.5. Bluebird Bio Inc Market Share
      6. 7.7.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    8. 7.8. Taxus Cardium Pharmaceutical Group Inc
      1. 7.8.1. Company Overview
      2. 7.8.2. Product/Service Portfolio
      3. 7.8.3. Taxus Cardium Pharmaceutical Group Inc Sales, Revenue, and Gross Margin
      4. 7.8.4. Taxus Cardium Pharmaceutical Group Inc Revenue and Growth Rate
      5. 7.8.5. Taxus Cardium Pharmaceutical Group Inc Market Share
      6. 7.8.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    9. 7.9. UniQure N.V
      1. 7.9.1. Company Overview
      2. 7.9.2. Product/Service Portfolio
      3. 7.9.3. UniQure N.V Sales, Revenue, and Gross Margin
      4. 7.9.4. UniQure N.V Revenue and Growth Rate
      5. 7.9.5. UniQure N.V Market Share
      6. 7.9.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    10. 7.10. Shire Plc
      1. 7.10.1. Company Overview
      2. 7.10.2. Product/Service Portfolio
      3. 7.10.3. Shire Plc Sales, Revenue, and Gross Margin
      4. 7.10.4. Shire Plc Revenue and Growth Rate
      5. 7.10.5. Shire Plc Market Share
      6. 7.10.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    11. 7.11. Cellectis S.A
      1. 7.11.1. Company Overview
      2. 7.11.2. Product/Service Portfolio
      3. 7.11.3. Cellectis S.A Sales, Revenue, and Gross Margin
      4. 7.11.4. Cellectis S.A Revenue and Growth Rate
      5. 7.11.5. Cellectis S.A Market Share
      6. 7.11.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    12. 7.12. Sangamo Therapeutics Inc
      1. 7.12.1. Company Overview
      2. 7.12.2. Product/Service Portfolio
      3. 7.12.3. Sangamo Therapeutics Inc Sales, Revenue, and Gross Margin
      4. 7.12.4. Sangamo Therapeutics Inc Revenue and Growth Rate
      5. 7.12.5. Sangamo Therapeutics Inc Market Share
      6. 7.12.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    13. 7.13. Gilead Lifesciences Inc
      1. 7.13.1. Company Overview
      2. 7.13.2. Product/Service Portfolio
      3. 7.13.3. Gilead Lifesciences Inc Sales, Revenue, and Gross Margin
      4. 7.13.4. Gilead Lifesciences Inc Revenue and Growth Rate
      5. 7.13.5. Gilead Lifesciences Inc Market Share
      6. 7.13.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    14. 7.14. Shanghai Sunway Biotech Co. Ltd
      1. 7.14.1. Company Overview
      2. 7.14.2. Product/Service Portfolio
      3. 7.14.3. Shanghai Sunway Biotech Co. Ltd Sales, Revenue, and Gross Margin
      4. 7.14.4. Shanghai Sunway Biotech Co. Ltd Revenue and Growth Rate
      5. 7.14.5. Shanghai Sunway Biotech Co. Ltd Market Share
      6. 7.14.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
  8. Chapter 8 Gene Therapy — Industry Analysis
    1. 8.1. Introduction and Taxonomy
    2. 8.2. Gene Therapy Market – Key Trends
      1. 8.2.1. Market Drivers
      2. 8.2.2. Market Restraints
      3. 8.2.3. Market Opportunities
    3. 8.3. Value Chain Analysis
    4. 8.4. Key Mandates and Regulations
    5. 8.5. Technology Roadmap and Timeline
    6. 8.6. Gene Therapy Market – Attractiveness Analysis
      1. 8.6.1. By Vectors
      2. 8.6.2. By Delivery Mode
      3. 8.6.3. By Indication
      4. 8.6.4. By Region
  9. Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers
    1. 9.1. Gene Therapy Industrial Chain Analysis
    2. 9.2. Downstream Buyers
    3. 9.3. Distributors/Traders List
  10. Chapter 10 Marketing Strategy Analysis
    1. 10.1. Marketing Channel
    2. 10.2. Direct Marketing
    3. 10.3. Indirect Marketing
    4. 10.4. Marketing Channel Development Trends
    5. 10.5. Economic/Political Environmental Change
  11. Chapter 11 Report Conclusion & Key Insights
    1. 11.1. Key Insights from Primary Interviews & Surveys Respondents
    2. 11.2. Key Takeaways from Analysts, Consultants, and Industry Leaders
  12. Chapter 12 Research Approach & Methodology
    1. 12.1. Report Description
    2. 12.2. Research Scope
    3. 12.3. Research Methodology
      1. 12.3.1. Secondary Research
      2. 12.3.2. Primary Research
      3. 12.3.3. Statistical Models
        1. 12.3.3.1. Company Share Analysis Model
        2. 12.3.3.2. Revenue Based Modeling
      4. 12.3.4. Research Limitations

      List of Figures

      Fig.1	Product Picture of Gene Therapy
Fig.2	Global Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.3	Global Gene Therapy Market Absolute Revenue Opportunity, 2016 – 2026 (USD Billion)
Fig.4	Global Gene Therapy Market Incremental Revenue Opportunity, 2020 – 2026 (USD Billion)
Fig.5	Global Gene Therapy Market Share, by Vectors , 2019 & 2026 (USD Billion)
Fig.6	Global Viral Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.7	Global Non-Viral Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.8	Global Gene Therapy Market Share, by Delivery Mode , 2019 & 2026 (USD Billion)
Fig.9	Global In Vivo Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.10	Global Ex Vivo Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.11	Global Gene Therapy Market Share, by Indication, 2019 & 2026 (USD Billion)
Fig.12	Global Neurological Diseases  Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.13	Global Cancer  Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.14	Global Duchenne Muscular Dystrophy Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.15	Global Hepatological Diseases Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.16	Global Others Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.17	Global Gene Therapy Market Share, by Region, 2019 & 2026 (USD Billion)
Fig.18	North America Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.19	U.S. Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.20	Canada Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.21	Europe Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.22	Germany Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.23	France Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.24	U.K. Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.25	Italy Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.26	Spain Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.27	Rest of Europe Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.28	Asia Pacific Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.29	China Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.30	Japan Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.31	India Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.32	South  Korea Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.33	South-East Asia Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.34	Rest of Asia Pacific Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.35	Latin America Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.36	Brazil Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.37	Mexico Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.38	Rest of Latin America Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.39	The Middle-East and Africa Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.40	GCC Countries Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.41	South Africa Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.42	Rest of Middle-East Africa Gene Therapy Market, 2016 – 2026 (USD Billion)
Fig.43	Competitor Market Share – Revenue
Fig.44	REGENBIO Inc Revenue and Growth Rate
Fig.45	REGENBIO Inc Market Share
Fig.46	Oxford BioMedica Plc Revenue and Growth Rate
Fig.47	Oxford BioMedica Plc Market Share
Fig.48	Dimension Therapeutics Inc Revenue and Growth Rate
Fig.49	Dimension Therapeutics Inc Market Share
Fig.50	Bristol-Myers Squibb Company Revenue and Growth Rate
Fig.51	Bristol-Myers Squibb Company Market Share
Fig.52	SANOFI Revenue and Growth Rate
Fig.53	SANOFI Market Share
Fig.54	Applied Genetics Technologies Corporation Revenue and Growth Rate
Fig.55	Applied Genetics Technologies Corporation Market Share
Fig.56	Bluebird Bio Inc Revenue and Growth Rate
Fig.57	Bluebird Bio Inc Market Share
Fig.58	Taxus Cardium Pharmaceutical Group Inc Revenue and Growth Rate
Fig.59	Taxus Cardium Pharmaceutical Group Inc Market Share
Fig.60	UniQure N.V Revenue and Growth Rate
Fig.61	UniQure N.V Market Share
Fig.62	Shire Plc Revenue and Growth Rate
Fig.63	Shire Plc Market Share
Fig.64	Cellectis S.A Revenue and Growth Rate
Fig.65	Cellectis S.A Market Share
Fig.66	Sangamo Therapeutics Inc Revenue and Growth Rate
Fig.67	Sangamo Therapeutics Inc Market Share
Fig.68	Gilead Lifesciences Inc Revenue and Growth Rate
Fig.69	Gilead Lifesciences Inc Market Share
Fig.70	Shanghai Sunway Biotech Co. Ltd Revenue and Growth Rate
Fig.71	Shanghai Sunway Biotech Co. Ltd Market Share
Fig.72	Market Dynamics
Fig.73	Global Gene Therapy – Value Chain Analysis
Fig.74	Key Mandates and Regulations
Fig.75	Technology Roadmap and Timeline
Fig.76	Market Attractiveness Analysis – By Vectors
Fig.77	Market Attractiveness Analysis – By Delivery Mode
Fig.78	Market Attractiveness Analysis – By Indication
Fig.79	Market Attractiveness Analysis – By Region
Fig.80	Gene Therapy Industrial Chain Analysis
Fig.81	Market Channels
Fig.82	Marketing Channel Development Trend
Fig.83	Growth in World Gross Product, 2008-2018

      List of Tables

      Table 1	Global Gene Therapy Market, 2019 & 2026 (USD Billion)
Table 2	Global Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
Table 3	Global Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
Table 4	Global Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
Table 5	Global Gene Therapy Market, by Region, 2016 – 2026 (USD Billion)
Table 6	North America Gene Therapy Market, by Country, 2016 – 2026 (USD Billion)
Table 7	North America Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
Table 8	North America Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
Table 9	North America Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
Table 10 Europe Gene Therapy Market, by Country, 2016 – 2026 (USD Billion)
Table 11 Europe Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
Table 12 Europe Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
Table 13 Europe Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
Table 14 Asia Pacific Gene Therapy Market, by Country, 2016 – 2026 (USD Billion)
Table 15 Asia Pacific Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
Table 16 Asia Pacific Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
Table 17 Asia Pacific Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
Table 18 Latin America Gene Therapy Market, by Country, 2016 – 2026 (USD Billion)
Table 19 Latin America Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
Table 20 Latin America Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
Table 21 Latin America Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
Table 22 The Middle-East and Africa Gene Therapy Market, by Country, 2016 – 2026 (USD Billion)
Table 23 The Middle-East and Africa Gene Therapy Market, by Vectors , 2016 – 2026 (USD Billion)
Table 24 The Middle-East and Africa Gene Therapy Market, by Delivery Mode , 2016 – 2026 (USD Billion)
Table 25 The Middle-East and Africa Gene Therapy Market, by Indication, 2016 – 2026 (USD Billion)
Table 26 Global Gene Therapy Market - Company Revenue Analysis, 2016 – 2019 (USD Billion)
Table 27 Global Gene Therapy Market - Company Revenue Share Analysis, 2016 – 2019 (%)
Table 28 Acquisitions and Mergers
Table 29 Market Drivers – Impact Analysis
Table 30 Market Restraints
Table 31 Market Opportunities
Table 32 Major Buyers of Gene Therapy
Table 33 Distributors/Traders of Gene Therapy by Region

Covid-19

Gene Therapy Market

The pandemic continues to cause unprecedented disruption across industries worldwide.Get detailed insights regarding the impact of COVID-19 on the market. Request Sample

Industry Major Market Players

  • REGENBIO Inc.
  • Oxford BioMedicaPlc
  • Dimension Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • SANOFI
  • Applied Genetics Technologies Corporation
  • Bluebird Bio Inc.
  • TaxusCardium Pharmaceutical Group Inc.
  • UniQure N.V.
  • Shire Plc
  • Cellectis S.A.
  • Sangamo Therapeutics Inc.
  • Gilead Lifesciences Inc.
  • Shanghai Sunway Biotech Co. Ltd.

Frequently Asked Questions

The governing factors that are responsible for the extensive growth of the global gene therapy market are the increasing prevalence of cancer and other targeted disorders coupled with rising availability measures to name a few.
According to Facts & Factors, global demand for gene therapy market is expected to generate revenue of around USD 12.9 Billion by end of 2026, growing at a CAGR of around 22.3% between 2021 and 2026.
North America is expected to witness the largest market share during the advent of the forecast owing to the rising prevalence of chronic diseases coupled with a high and growing healthcare expenditure to name a few.
The key participants in the global gene therapy market are REGENBIO, Inc., Oxford BioMedica Plc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, and Applied Genetics Technologies Corporation, to name a few.
why choose fnf
key questions answers

Related Reports

report img

Anesthesia Gas Mixers Market Report 2021 – 2026

Facts Factors recently published a report on theglobal anesthesia gas mixers market. The report encompasses market statistics and analytics. The market value of the anesthesia gas mixers market was witnessed to be USD 500 Million in 2020 and with growth at a CAGR of 6% is projected to reach a val...

Published Date : 28-Dec-2021 | | Category : | Pages : 171 | Format : Read more

Inquiry for Buying Request Sample
report img

Anesthesia Equipment Market Report 2021 – 2026

According to Facts Factors, the report on the Global Anesthesia Equipment Market encompasses the complete history and forecast details. In this report, the market value was witnessed to be around USD 11 Billion in 2020 and with a CAGR of 6.5% will acquire USD 16 Billion by 2026. Report Overview...

Published Date : 28-Dec-2021 | | Category : | Pages : 171 | Format : Read more

Inquiry for Buying Request Sample

paypal
Copyright © 2021, All Rights Reserved, Facts and Factors